A Phase 4 interventional study of Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution in Glaucoma, sponsored by Aerie Pharmaceuticals. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.
Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing netarsudil in Glaucoma — 2 open to participants now, 2 under way, none of them phase 3. netarsudil · Glaucoma.
Among the 11 studies testing netarsudil in Glaucoma, this one is the 6th largest by enrollment, is the only one that started in 2022, is one of 4 in phase 4, and was the 7th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →2 of the 11 studies testing netarsudil in Glaucoma are open now, in 1 country. Recruiting first, the newest first:
Brett King · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 18+
By country, each count listing its studies:
netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 5 · Phase 4 4
First in 2012; this study’s year is marked. 1 started in 2022.
This study's enrollment of 136 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 136 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 6 most frequent:
This study is registered under Aerie Pharmaceuticals, one of the names counted as Alcon. Under that name alone:
Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
93 studies in Glaucoma by Alcon: none open now, none under way, none of them phase 3. Of 92 finished, 35 (38%) have results posted.
Among the 93 studies in Glaucoma by Alcon, this one is the 33rd largest by enrollment of the 77 interventional ones that give a count, is the only one that started in 2022, is one of 37 in phase 4, and was the 90th registered.
Alcon’s Glaucoma studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing netarsudil in Glaucoma, from their registry updates:
Among Alcon’s 93 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).
Enrollment will be stratified according to subject's IOP-lowering medical therapy regimen as follows:
Aerie Pharmaceuticals was acquired by Alcon Research LLC on November 22, 2022.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, one drop in each eye in the evening for 12 weeks
Drug: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Drug page: Netarsudil
Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Also known as: Rocklatan®
Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12
IOP was measured using Goldmann applanation tonometry at the Baseline and Week 12 visits. One eye (study eye) contributed data to this analysis. A negative value indicates an improvement in IOP. No hypothesis testing was prespecified for this endpoint.
Time frame: Baseline (Day 0 pretreatment), Week 12
Participants were recruited from 21 investigative sites located in the United States.
| Milestone | Rocklatan (Latanoprost Mono) | Rocklatan (Latanoprost +1) | Rocklatan (Latanoprost +2) |
|---|---|---|---|
| Started | 61 | 45 | 30 |
| Completed | 54 | 37 | 25 |
| Not completed | 7 | 8 | 5 |
| Withdrew: Adverse event | 4 | 4 | 0 |
| Withdrew: Patient lost to follow-up | 0 | 0 | 1 |
| Withdrew: Patient withdrawal | 2 | 4 | 2 |
| Withdrew: Investigator decision | 1 | 0 | 1 |
| Withdrew: Enrolled in error | 0 | 0 | 1 |
IOP was measured using Goldmann applanation tonometry at the Baseline and Week 12 visits. One eye (study eye) contributed data to this analysis. A negative value indicates an improvement in IOP. No hypothesis testing was prespecified for this endpoint.
| percent change | Rocklatan (Latanoprost Mono) | Rocklatan (Latanoprost +1) | Rocklatan (Latanoprost +2) | Rocklatan Total |
|---|---|---|---|---|
| Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12 | -21.2 ± 17.46 | -15.7 ± 21.91 | -16.9 ± 17.31 | -18.5 ± 18.96 |
Collected over Adverse events (AEs) were collected for the duration of individual participation in the study, approximately 12 weeks (±7 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rocklatan (Latanoprost Mono) | 0/61 (0%) | 0/61 (0%) | 9/61 (14.8%) |
| Rocklatan (Latanoprost +1) | 0/45 (0%) | 0/45 (0%) | 10/45 (22.2%) |
| Rocklatan (Latanoprost +2) | 0/30 (0%) | 1/30 (3.3%) | 6/30 (20%) |
| Event | Rocklatan (Latanoprost Mono) | Rocklatan (Latanoprost +1) | Rocklatan (Latanoprost +2) |
|---|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 0/61 | 0/45 | 1/30 |
| Event | Rocklatan (Latanoprost Mono) | Rocklatan (Latanoprost +1) | Rocklatan (Latanoprost +2) |
|---|---|---|---|
| Conjunctival hyperaemiaEye disorders | 9/61 | 10/45 | 6/30 |
Safety Population: All subjects who have received at least 1 dose of study medication
| Age, Continuous(years) | Rocklatan (Latanoprost Mono) | Rocklatan (Latanoprost +1) | Rocklatan (Latanoprost +2) | Total |
|---|---|---|---|---|
| Mean | 67.4 ± 11.2 | 71.1 ± 10.06 | 69.3 ± 11.60 | 69.0 ± 10.97 |
| Sex: Female, Male(Participants) | Rocklatan (Latanoprost Mono) | Rocklatan (Latanoprost +1) | Rocklatan (Latanoprost +2) | Total |
|---|---|---|---|---|
| Female | 32 | 23 | 14 | 69 |
| Male | 29 | 22 | 16 | 67 |
| Ethnicity (NIH/OMB)(Participants) | Rocklatan (Latanoprost Mono) | Rocklatan (Latanoprost +1) | Rocklatan (Latanoprost +2) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 13 | 7 | 10 | 30 |
| Not Hispanic or Latino | 48 | 38 | 20 | 106 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Rocklatan (Latanoprost Mono) | Rocklatan (Latanoprost +1) | Rocklatan (Latanoprost +2) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 | 4 |
| Asian | 1 | 2 | 1 | 4 |
| Black or African American | 13 | 9 | 11 | 33 |
| White | 46 | 32 | 16 | 94 |
| Other | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2022 to primary completion in Mar 2023, 11 months.
Results were first posted in Apr 2024, 1 year after primary completion.
Of 44 phase 4 interventional studies under Glaucoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 66. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Netarsudil